drugset / Trial / NCT00239330

Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy

NCT00239330

Phase 3 Completed 824 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.

Timeline

Start
2003-06
Primary completion
2005-02
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 10 mg

Indications